TRIUMPH-1 Sunday Coverage Consolidation: Broadly Favorable Across Leerink, RBC, Mainstream Health Press Through the Weekend Cycle
The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.